The Japan-based global specialist in ophthalmology and dermatology treatments will use Albucult as a key component in its new therapy, which will be the first of its kind for the treatment of severe and moderate dry eye conditions.
Albucult is manufactured by Novozymes’ long-term technology partner, Kaketsuken, based in Kumamoto, Japan and marketed by Novozymes worldwide.
The prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. Novozymes says Albucult confers a number of benefits to the development of R-Tech Ueno’s new therapy, including an exceptional purity profile and batch-to-batch consistency.
You may also like
You may also like
Safe, consistent and sustainable hyaluronic acid
Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Let enzymes do the work
The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.